CRISPR/Cas9 therapy extends life span in progeria mice and reduces accelerated aging

CRISPR/Cas9 can prolong life in mice, improve health and suppress aging.

The findings were published in Nature Medicine on February 18, 2019. They highlight a novel CRISPR/Cas9 gene-editing treatment that can suppress accelerated aging in mice with Hutchinson Gilford progeria, a rare genetic condition that also affects humans. This treatment offers important insights into the molecular mechanisms involved in accelerated ageing, as well how to reduce toxic protein via gene therapy.

Juan Carlos Izpisua Belmonte is a professor at Salk’s Gene Expression Laboratory, and the senior author of this paper. He says, \”Aging is complex, as cells begin to lose functionality. It is therefore critical that we find effective ways to understand the molecular mechanisms of aging.\” \”Progeria makes a great aging model, because we can quickly develop an intervention and refine it.

Progeria, a degenerative disorder with an early onset that progresses rapidly, is the most severe form. It’s caused by a mutation of the LMNA gene. Progeria is a degenerative disorder that affects both mice and humans. It causes DNA damage, cardiac dysfunction, and a dramatically shorter life expectancy. Normal expression of the LMNA gene produces lamin C and lamin A, but progeria causes lamin A production to shift. Progerin, a toxic and shortened form of lamin A, accumulates as we age. It is more pronounced in progeria patients.


Leave a Reply

Your email address will not be published. Required fields are marked *